GPI attending HTAi Annual Meeting
GPI will be presenting two research abstracts at the HTAi Annual Meeting, one as a poster presentation, and one as an oral presentation - 29 June 2022.
25-29 June 2022, In-Person & Virtual Conference
GPI will be attending and presenting our research at the HTAi annual meeting, held in Utrecht, The Netherlands on 25-29 June 2022. Our representatives will be onsite and on hand to discuss how GPI can optimise your pricing and market access decision-making in 2022 and beyond. In addition, GPI will be presenting our research poster ‘Exploring the relationship between price and outcome of health’ in addition to our oral presentation ‘The national pricing and reimbursement process in China, a 2021 update’. The poster will be available throughout the conference, and the oral presentation will be taking place on Wednesday 29 June, 111:05am CEST.
HTAi Research Poster
Exploring the relationship between price and outcome of health
For the purpose of controlling medical care expenditure and increasing value for money within the healthcare system, Japan introduced its first formal health technology assessment (HTA) in April 2019, driven by a cost-effectiveness analysis (CEA) approach to adjust the price of already reimbursed products. In this HTAi poster, we would lay out the price setting and adjustment process of medicines in Japan and explore the relationship between price and outcome of the CEA by assessing all HTAs published until 29th November 2021.
HTAi Research Poster
The national pricing and reimbursement process in China, a 2021 update
Wednesday 29 June 11:05am – 11:15am
The Chinese National Reimbursement Drug List (NRDL) was founded in the early 2000’s. Since its establishment, the health system in China has undergone reforms that have resulted in changes to the reimbursement process and how new drugs are launched within the market. It is important for manufacturers to understand how such changes impact access opportunities in China. In this HTAi poster, we would like to evaluate the evolving price and reimbursement landscape in China and understand the perspectives of payers and policy experts within the field, using both secondary and primary research..
Share the Article: